These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38721144)

  • 1. Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
    Zhao Y; Mu Z; Liang D; Zhang T; Zhang X; Sun D; Sun Y; Liang J; Lin Y
    Front Endocrinol (Lausanne); 2024; 15():1354426. PubMed ID: 38721144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China.
    Liu Q; Yin M; Li G
    Front Endocrinol (Lausanne); 2021; 12():774275. PubMed ID: 34975751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.
    Phan HT; Jager PL; van der Wal JE; Sluiter WJ; Plukker JT; Dierckx RA; Wolffenbuttel BH; Links TP
    Eur J Endocrinol; 2008 Jan; 158(1):77-83. PubMed ID: 18166820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation.
    Chung JK; Park YJ; Kim TY; So Y; Kim SK; Park DJ; Lee DS; Lee MC; Cho BY
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):215-21. PubMed ID: 12153600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating Antithyroglobulin Antibody As a Prognostic Marker for Differentiated Thyroid Cancer: A Meta-Analysis and Systematic Review.
    Lee ZJO; Eslick GD; Edirimanne S
    Thyroid; 2020 Nov; 30(11):1601-1612. PubMed ID: 32345152
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Lymph Node Metastasis on Change of Positive Thyroglobulin Antibody in Differentiated Thyroid Carcinoma after Initial Treatment.
    Zhang T; Song LP; Zhao T; Gao W; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):539-543. PubMed ID: 28877833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer.
    Jo K; Lim DJ
    Korean J Intern Med; 2018 Nov; 33(6):1050-1057. PubMed ID: 30396251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.
    Spencer C; LoPresti J; Fatemi S
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):394-404. PubMed ID: 25122493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer.
    Lupoli GA; Okosieme OE; Evans C; Clark PM; Pickett AJ; Premawardhana LD; Lupoli G; Lazarus JH
    J Clin Endocrinol Metab; 2015 Jan; 100(1):100-8. PubMed ID: 25322272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of papillary thyroid cancers with positive serum thyroglobulin antibody after total thyroidectomy.
    Kuo SF; Chao TC; Chang HY; Hsueh C; Lin CL; Chiang KC; Chuang WY; Chen YC; Lin JD
    Asian J Surg; 2017 May; 40(3):186-192. PubMed ID: 26553529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.
    Durante C; Tognini S; Montesano T; Orlandi F; Torlontano M; Puxeddu E; Attard M; Costante G; Tumino S; Meringolo D; Bruno R; Trulli F; Toteda M; Redler A; Ronga G; Filetti S; Monzani F;
    Thyroid; 2014 Jul; 24(7):1139-45. PubMed ID: 24702238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
    Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
    Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
    Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
    Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate‑ and high‑risk differentiated thyroid cancer patients: a bi-center retrospective study.
    Wen R; Zhao M; Chen C; Yang Y; Zhang B
    Endocrine; 2024 Jun; 84(3):989-998. PubMed ID: 38085420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without
    Matrone A; Latrofa F; Torregrossa L; Piaggi P; Gambale C; Faranda A; Ricci D; Agate L; Molinaro E; Basolo F; Vitti P; Elisei R
    Thyroid; 2018 Jul; 28(7):871-879. PubMed ID: 29860933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibody.
    Jo K; Kim MH; Lim Y; Jung SL; Bae JS; Jung CK; Kang MI; Cha BY; Lim DJ
    Eur J Endocrinol; 2015 Oct; 173(4):489-97. PubMed ID: 26208979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
    Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.
    Rosario PW; Siman TL; Calsolari MR
    Endocrine; 2015 May; 49(1):170-4. PubMed ID: 25209895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.